Nomenclature for human CYP2D6 alleles

Pharmacogenetics

Volumn 6, Issue 3, 1996, Pages 193-200

  Daly, A K ^a   Brockmoller J ^b   Broly, F ^c   Eichelbaum, M ^d   Evans, W E ^e   Gonzalez, F J ^f   Huang, J D ^g   Idle, J R ^a   Ingelman Sundberg, M ^h   Ishizaki, T ⁱ   Jacqz Aigrain, E ^j   Meyer, U A ^k   Nebert, D W ^l   Steen, V M ^m   Wolf, C R ⁿ   Zanger, U M ^d  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIV LILLE   (France)

^d DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^h KAROLINSKA INSTITUTE   (Sweden)

ⁱ NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^j HÔPITAL ROBERT DEBRÉ   (France)

^k UNIVERSITY OF BASEL   (Switzerland)

^l UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^m HAUKELAND UNIVERSITY HOSPITAL   (Norway)

ⁿ UNIVERSITY OF DUNDEE   (United Kingdom)

more..

Author keywords

Allele nomenclature; CYP2D6

Indexed keywords

CYTOCHROME P450 ISOENZYME;

ALLELE; ARTICLE; CLASSIFICATION; GENOME; MUTATION; NOMENCLATURE; PRIORITY JOURNAL; STANDARDIZATION;

ALLELES; CYTOCHROME P-450 CYP2D6; GENE AMPLIFICATION; GENOTYPE; GUIDELINES; HUMANS; MULTIGENE FAMILY; MUTATION; TERMINOLOGY;

ROMAN;

EID: 8944256082     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199606000-00001     Document Type: Article

References (40)

1. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues, F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. 1995: submitted for publication.
2. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991: 10, 545-558.
3. Broly F, Meyer UA. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene. Pharmacogenetics 1993: 3, 123-130.
4. Broly F, Marez D, Sabbagh N, Legrand M, Boone P, Meyer UA. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Pharmacogenetics 1995: 5, 373-384.
5. Cholerton S, Daly AK, Idle JR. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 1992: 13, 434-438.
6. Dahl M-L, Johansson I, Palmertz MP, Ingelman-Sundberg M, Sjöqvist F. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 1992: 51, 12-17.
7. Dahl M, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995: 274, 516-520.
8. Daly AK, Armstrong M, Monkman SC, Idle ME, Idle JR. The genetic and metabolic criteria for the assignment of debrisoquine hydroxylation (cytochrome P450IID6) phenotypes. Pharmacogenetics 1991: 1, 33-41.
9. Daly AK, Leathart JBS, London SJ, Idle JR. An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution. Human Genet 1995: 95, 337-341.
10. Daly AK, Fairbrother KS, Andreassen OA, London SJ, Idle JR, Steen VM. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Pharmacogenetics 1996: 6, in press.
11. deMorais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994a: 269, 15419-15422.
12. deMorais SM, Wilkinsong GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994b: 46, 594-598.
13. Evert B, Grise E-U, Eichelbaum M. A missense mutation in exon 6 of the CYP2D6 gene leading to a histodine to proline exchange is associated with the poor metabolizer phenotype of sparteine. Naunyn-Schmiedeberg's Arch Pharmacol 1994a: 350, 434-439.
14. 1795 in exon 3 generates a premature stop codon. Pharmacogenetics 1994b: 4, 271-274.
15. Fernandez-Salguero P, Hoffman SMG, Cholerton C, Mohrenweiser H, Raunio H, Rautio A, Pelkonen O, Huang J-d, Evans WE, Idle JR, Gonzalez FJ. A genetic polymorphism of coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet 1995: 57, 651-600.
16. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 1991: 48, 943-950.
17. Gough AC, Miles JS, Spurr NK, Moss JE, Gaedigk A, Eichelbaum M. Wolf CR. Identification of the primary gene defect at the cytochrome P450 CTP2D locus. Nature 1990: 347, 773-776.
18. 1934 to A base change in intron 3 of a mutant CTP2D6 allele results in an aberrant 3′ splice recognition site. Am J Hum Genet 1990: 47, 994-1001.
19. Ingelman-Sundberg M, Oscarson M, Persson I, Masimirembwa CM, Dahl M-L, Bertilsson L, Sjöqvist F, Johansson I. Genetic polymorphism of human drug metabolizing enzymes. Recent aspects on polymorphic forms of cytochromes P450. In: Alvan G, Balant LP, Bechtel PR, Boobis AR, Gram LF, Paintaud G, Pithan K (eds.) European conference on specificity and variability in drug metabolism, Luxembourg: EU, 1995, 93-110.
20. Johansson I, Lundqvist E, Bertilsson L, Dahl M-L, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993: 90, 11825-11829.
21. Johansson I, Oscarson M, Yue Q-Y, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxyalation. Mol Pharmacol 1994: 46, 252-259.
22. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA. Multiple mutations of the human cytochrome P45011D6 gene (CYP2D6) in poor metabolisers of debrisoquine. J Biol Chem 1990: 265, 17209-17214.
23. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D6) locus: sequence and identification of a polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 1989: 45, 889-905.
24. Marez D, Sabbagh N, Legrand M, Lo-Guidice JM, Boone P, Broly F. A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype. Pharmacogenetics 1995a: 5, 305-311.
25. Marez D, Legrand M, Sabbagh N, Lo-Guidice J-M, Boone P, Broly F. An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine. Human Genetics 1995b: submitted.
26. Masimirembwa C, Persson I, Bertilson L, Hasler J, Ingelman-Sundberg M. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity, 1996: submitted.
27. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. P450 superfamily: update on new sequences, gene mapping, accession numbers, and nomenclature. Pharmacogenetics 1996: 6, in press.
28. Panserat S, Mura C, Gerard N, Vincent-Viry M, Galteau MM, Jacqz-Aigrain E, Krishnamorthy R. DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolisers. Hum Genet 1994: 94, 401-406.
29. Panserat S, Mura C, Gerard N, Vincent-Viry M, Galteau MM, Jacqz-Aigrain E, Krishnamorthy R. An unequal cross-over event within the CYP2D6 gene cluster generates a chimeric CYP2D7/CYP2D6 gene which is associated with the poor metabolizer phenotype. Br J Clin Pharmacol 1995: 40, 361-367.
30. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the RI44C allelic variant of CYP2C9. Pharmacogenetics 1994: 4, 39-42.
31. Sabbagh N, Brice A, Marez D, Durr A, Legrand M, Lo Guidice J-M, Destee A, Agid Y, Broly F. CYP2D6 polymorphism in familial and sporadic Parkinson's disease. Pharmacogenetics 1996: submitted.
32. Sachse C, Brockmöller J, Bauer S, Reum T, Roots I. A rare insertion of T226 in exon 1 of CYP2D6 causes a frameshift and is associated with the poor metabolizer phenotype: CYP2D6*15. Pharmacogenetics 1996: 6, 269-272.
33. Saxena R, Shaw GL, Relling MV, Frame JN, Moir DT, Evans WE, Caporaso N, Weiffenbach B. Identification of a new variant CYP2D6 single base pair deletion in exon 3 and its association with the poor metabolizer phenotype. Hum Mol Genet 1994: 3, 923-926.
34. Shows TB, McAlpine PJ, Boucheix C, Collins FS, Conneally PM, Frezal J, Gershowitz H, Goodfellow PN, Hall IG, lssitt P, Jones CA, Knowles BB, Lewis M, McKusick VA, Meisler M, Morion NE, Rubinstein P, Schanfield MS, Schmickel RD, Skolnick MH, Spence MA, Sutherland GR, Traver M, Van Cong N, Willard HF. Guidelines for human gene nomenclature. Cytogenet Cell Genet 1987: 46, 11-28.
35. Steen VM, Molven A, Aarskog NK, Gulbrandsen, A-K. Homologous unequal cross-over involving a 2.8kb direct repeat as a mechanism for the generation of allelic variants of the human cytochrome P450 CYP2D6 gene. Hum Mol Genet 1995: 4, 2251-2257.
36. Sullivan TH, Ghanayem BI, Bell DA, Zhang Z, Kaminsky LS, Shefield GM, Miners JO, Birkett DJ, Goldstein JA. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996, in press.
37. Tyndale R, Aoyama T, Broly F, Matsunaga T, Inaba T, Kalow W, Gelboin HV, Meyer UA, Gonzalez FJ. Identification of a new CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics 1991: 1, 26-32.
38. Vatsis KP, Weber WW, Bell DA, Dupret J-M, Evans DAP, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV, Sim E, Suzuki T, Yamazoe Y. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995: 5, 1-17.
39. Wang S (1992). Phenotypes and genotypes of debrisoquine hydroxylation polymorphism in Chinese. Master's thesis. National Cheng Kung University, Tainan, Taiwan.
40. Yokota H, Tamura S, Furuya H, Kimura S, Watanbe M, Kanazawa I, Kondo I, Gonzalez FJ. Evidence for a new variant allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics 1993: 3, 256-263.